FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Vuori Kristiina MD</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol Bionano Genomics, Inc [ BNGO ]								ck all applic	able)	g Pers	son(s) to Iss			
(Last) (First) (Middle) C/O BIONANO GENOMICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 08/17/2021								Officer below)	(give title		Other (s below)	specify	
9540 TOWNE CENTRE DRIVE, SUITE 100					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SAN DII	EGO C.	A	92121								X		led by Mor	orting Perso n One Repo				
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				ate	Execution Date,		3. 4. Securities Acquir Disposed Of (D) (In: 5)				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	P	rice		action(s)			(111341. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date (Month/Day/Year)  3A. Deemed Execution Date, if any (Month/Day/Year)			Cod	ansaction of ode (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Ar of Securities Underlying Derivative Set (Instr. 3 and 4)			ies g Secu		8. Price of Derivative Security (Instr. 5)		Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Ownership	Beneficial Ownership t (Instr. 4)		
				Cod	de V	(A)	(D)	Date Exercisable		xpiration ate	Title	or	ount nber res					
Stock Option (right to buy)	\$5.34	08/17/2021		A		40,751		(1)	0	8/17/2031	Common Stock	40,	751	\$0.00	40,751	1	D	

## **Explanation of Responses:**

1. The shares will vest in equal monthly installments over the 12 months following June 10, 2021, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).

## Remarks:

/s/ R. Erik Holmlin, Attorneyin-fact

08/19/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.